Sichuan Biokin chases Hong Kong listing after BSM drug deal
The biopharma company has yet to market any products but one of its antibody-drug conjugates is being jointly developed in a lucrative collaboration with Bristol Myers Squibb Key Takeaways: Sichuan…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
